Hidradenitis Suppurativa Treatment

Iltefat Hamzavi, MD, outlines how symptom questionnaires and comorbidity screening shape hidradenitis suppurativa care. Researchers compared three approved biologics for the condition.

Iltefat Hamzavi, MD, says symptom questionnaires, comorbidity screening, wound care, and procedures are key to hidradenitis suppurativa care. Jennifer Hsiao, MD, notes that defining treatment response improves adherence and success.

A new analysis compared one-year results for three biologics approved for adults with moderate to severe hidradenitis suppurativa: bimekizumab, secukinumab, and adalimumab. The comparison used a statistical method to match patient characteristics across existing trial data.

The findings showed that bimekizumab had higher odds of clinical response at every threshold measured compared to secukinumab. It also linked to greater quality-of-life improvements, fewer flares, and bigger reductions in painful inflammatory nodules and draining tunnels.

Against adalimumab, bimekizumab was more likely to reach the 50 and 75 percent response thresholds and showed greater reductions in nodules and tunnels. Bimekizumab held onto its favorable results in patients who had already been on a biologic before.

The drug works by blocking two inflammatory proteins, IL-17A and IL-17F. This analysis gives patients and their dermatologists more to weigh when choosing a biologic, especially for people who have already tried one and are considering a switch.

For those with milder hidradenitis suppurativa, topical options are being studied. The analysis did not compare safety, as it was reported inconsistently across the studies.

Until a true head-to-head trial happens, analyses like this provide more information for patients and dermatologists. Iltefat Hamzavi, MD, and Jennifer Hsiao, MD, emphasize the importance of symptom questionnaires and comorbidity screening in hidradenitis suppurativa care.

Key facts

  • Bimekizumab had higher odds of clinical response compared to secukinumab.
  • Bimekizumab linked to greater quality-of-life improvements and fewer flares.
  • The analysis compared one-year results for three biologics approved for hidradenitis suppurativa.
  • Bimekizumab works by blocking two inflammatory proteins, IL-17A and IL-17F.

Three perspectives

Neutral

The analysis provides more information for patients and dermatologists choosing a biologic for hidradenitis suppurativa. The findings show bimekizumab had higher odds of clinical response compared to secukinumab. More research is needed to fully compare the safety and efficacy of the biologics.

Positive

The analysis offers hope for patients with hidradenitis suppurativa, as bimekizumab showed favorable results in clinical response and quality-of-life improvements. The drug's ability to block two inflammatory proteins provides a promising treatment option.

Negative

The analysis has limitations, as it did not compare safety and relied on a statistical method to match patient characteristics. More research is needed to fully understand the efficacy and safety of the biologics, and to provide patients with the best treatment options.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Study identifies racial differences in pancreatic cancer tumor cells
Next storyStudy identifies racial differences in pancreatic cancer tumor cells

All sections

Edition